Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - European journal of …, 2020 - Wiley Online Library
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė, P Henriksen… - European Journal of …, 2020 - hal.science
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from theCardio-Oncology Study Groupof theHeart Failure …
R Pudil, C Mueller, J Celutkiene… - European …, 2020 - scholarlypublications …
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from theCardio-Oncology Study Groupof theHeart Failure …
R Pudil, C Mueller, J Celutkiene… - European Journal of …, 2020 - research.rug.nl
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - European Journal of …, 2020 - zora.uzh.ch
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė, PA Henriksen… - 2020 - publications.goettingen-research …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position
statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the …
statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - European Journal of …, 2020 - europepmc.org
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - … journal of heart …, 2020 - pubmed.ncbi.nlm.nih.gov
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - European journal of …, 2020 - folia.unifr.ch
English Serum biomarkers are an important tool in the baseline risk assessment and
diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer …
diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė, PA Henriksen… - European journal of …, 2020 - sonar.ch
English Serum biomarkers are an important tool in the baseline risk assessment and
diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer …
diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer …